Carlyle Group LP (CG), Monsanto Company (MON): E I Du Pont De Nemours And Co (DD)’s Really Being Strengthened by Going to Seed

Page 1 of 2

I can’t quite claim to have monitored E I Du Pont De Nemours And Co (NYSE:DD) since its founding back in 1802 as a gunpowder manufacturer. In the past few years, however, the big Delaware company has initiated a somewhat quiet restructuring that promises to make it far less cyclical and more compelling for investors.

Steadily buying and selling

In early 2011, for instance, the company acquired Danisco, a global enzyme and specialty food ingredients company based in Denmark. For $6.3 billion, including the assumption of debt, E I Du Pont De Nemours And Co (NYSE:DD) added a unit that, as is the case with its own fast-expanding agricultural unit, will be driven in the years and decades to come by our planet’s expected dramatic population growth.

E I Du Pont De Nemours And Co

Conversely, in 2012 the company accepted nearly $5 million from private equity’s Carlyle Group LP (NASDAQ:CG) for its car paint unit. The deal turned out to be one of more than a dozen salted away by Carlyle during the year.

Those deals, along with other trends at the company, indicate that the significant restructuring largely initiated during the reign of the company’s competent CEO, Ellen Kuhlman, is likely to continue and perhaps expand. As was manifested strongly in the second quarter, E I Du Pont De Nemours And Co (NYSE:DD) continues to follow in the footsteps of its rival Monsanto Company (NYSE:MON) in emphasizing agriculture and related areas (read Danisco’s food and enzyme products), while shedding its former base in more cyclical chemicals operations.

The new backbone

At was expected, DuPont’s ag unit — largely bioengineered seeds and pesticides — led the way in the quarter, with revenues that constituted 37% of the total and expanded by 7%. But as I noted at the time, the performance chemicals segment saw its revenue dip by 15% and its operating earnings plunge by 56%.

Kuhlman et al. noted unequivocally at release time that they’d be better off without performance chemicals, which was hit hardest by excessive capacity and low prices for titanium dioxide, a whitening agent used in a host of products. A figurative “for sale” sign has clearly been placed in front of the unit, with the notion that it’d fetch about $10 billion, potentially from one of Carlyle Group LP (NASDAQ:CG)’s private equity brethren.

It’s noteworthy, however, that E I Du Pont De Nemours And Co (NYSE:DD)’s isn’t the only titanium dioxide unit on the market. Huntsman Corporation (NYSE:HUN), which also manufactures the agent, will similarly be vying for buyers’ attention for its own operation.

A brightening in darkest Africa

Back on the debit side of the ledger, soon after announcing its second-quarter results, DuPont told us that, following a three-year struggle, it had completed the acquisition of South Africa’s Pannar Seed. The purchase, which was first announced in September 2010, obviously will further expand agriculture’s base at the company. And with it (and assuming that performance chemicals is jettisoned), I’m projecting that the three-segment agriculture- and food-related group will easily account for as much as 75% of total revenues by the end of 2015.

Let’s look at what all this means to likely sources of the company’s revenues in the not-too-distant future. In the most recent quarter, agriculture and its related segments accounted for nearly 49% of E I Du Pont De Nemours And Co (NYSE:DD)’s total sales. Where I went to school, that’s about half. But had performance chemicals been unloaded before June 30, agriculture, biosciences, and nutrition would have been responsible for nearly 60% of the total.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!